Skip to main content
. Author manuscript; available in PMC: 2021 Jul 17.
Published in final edited form as: Int J Cancer. 2018 May 2;143(6):1315–1326. doi: 10.1002/ijc.31529

Figure 1. HRs for cancer-specific and non-cancer mortalities among users of PPIs or H2RAs.

Figure 1

Forest plots show adjusted HRs and 95% CIs for cancer-specific and non-cancer mortality among Danish cancer patients estimated using Cox proportional hazards regression models and stratified according to nine major cancer sites.

(A) Values for PPI users with ≥2 PPI prescriptions within 0-6 months after the cancer diagnosis compared to PPI nonusers with <2 PPI prescriptions in the same period.

(B) Values for PPI users with ≥2 PPI prescriptions within 0-6 months after the cancer diagnosis compared to H2RA users with ≥2 H2RA prescriptions in the same period.

(C) Values for H2RA users with ≥2 H2RA prescriptions within 0-6 months after the cancer diagnosis compared to nonusers with <2 H2RA prescriptions in the same period.

The corresponding values for figures A and B are shown in Supplementary Table 2 and unadjusted estimates for cancer mortality for post-diagnostic PPI and H2RA users versus nonusers in Supplementary Figures 2A and B.